Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer.
Berger, S., Procko, E., Margineantu, D., Lee, E.F., Shen, B.W., Zelter, A., Silva, D.A., Chawla, K., Herold, M.J., Garnier, J.M., Johnson, R., MacCoss, M.J., Lessene, G., Davis, T.N., Stayton, P.S., Stoddard, B.L., Fairlie, W.D., Hockenbery, D.M., Baker, D.(2016) Elife 5
- PubMed: 27805565 
- DOI: https://doi.org/10.7554/eLife.20352
- Primary Citation of Related Structures:  
5JSB, 5JSN - PubMed Abstract: 
Many cancers overexpress one or more of the six human pro-survival BCL2 family proteins to evade apoptosis. To determine which BCL2 protein or proteins block apoptosis in different cancers, we computationally designed three-helix bundle protein inhibitors specific for each BCL2 pro-survival protein ...